Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
NCT00729924
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Raltegravir
Sponsor
Vanderbilt University